Compare Stocks: ANTX, ZVRA, IVA, and AQST

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANTX Anthem	$4.40	$5.52	$1.00 ▼ $7.19	$166.06M	-0.98	306,377 shs	442,134 shs
AQST Aquestive Therapeutics	$4.78	$4.69	$2.93 ▼ $7.55	$599.95M	1.49	2.07 million shs	1.69 million shs
IVA Inventiva	$3.16	$4.21	$3.11 ▼ $7.98	$752.05M	0.79	2.71 million shs	2.79 million shs
ZVRA Zevra Therapeutics	$11.39	$11.52	$8.01 ▼ $15.03	$676.34M	0.98	982,393 shs	730,721 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANTX Anthem	0.00%	-22.94%	-18.67%	-3.30%	+246.46%
AQST Aquestive Therapeutics	0.00%	+5.05%	0.00%	+17.73%	-26.91%
IVA Inventiva	0.00%	-11.24%	-21.39%	-26.51%	-30.55%
ZVRA Zevra Therapeutics	0.00%	+14.01%	-5.16%	-13.58%	+3.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANTX Anthem	$4.40	$5.52	$1.00 ▼ $7.19	$166.06M	-0.98	306,377 shs	442,134 shs
AQST Aquestive Therapeutics	$4.78	$4.69	$2.93 ▼ $7.55	$599.95M	1.49	2.07 million shs	1.69 million shs
IVA Inventiva	$3.16	$4.21	$3.11 ▼ $7.98	$752.05M	0.79	2.71 million shs	2.79 million shs
ZVRA Zevra Therapeutics	$11.39	$11.52	$8.01 ▼ $15.03	$676.34M	0.98	982,393 shs	730,721 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANTX Anthem	0.00%	-22.94%	-18.67%	-3.30%	+246.46%
AQST Aquestive Therapeutics	0.00%	+5.05%	0.00%	+17.73%	-26.91%
IVA Inventiva	0.00%	-11.24%	-21.39%	-26.51%	-30.55%
ZVRA Zevra Therapeutics	0.00%	+14.01%	-5.16%	-13.58%	+3.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANTX Anthem	2.33	Hold	$9.00	104.55% Upside
AQST Aquestive Therapeutics	2.83	Moderate Buy	$8.60	79.92% Upside
IVA Inventiva	3.00	Buy	$15.86	401.81% Upside
ZVRA Zevra Therapeutics	3.00	Buy	$27.14	138.30% Upside

Current Analyst Ratings Breakdown

Latest ANTX, ZVRA, IVA, and AQST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	IVA Inventiva	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
10/2/2026	ANTX Anthem	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/2/2026	IVA Inventiva	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.00 ➝ $18.00
9/23/2026	ZVRA Zevra Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/16/2026	IVA Inventiva	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/15/2026	IVA Inventiva	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $14.00
9/10/2026	AQST Aquestive Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$11.00
8/24/2026	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/20/2026	ZVRA Zevra Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00
8/19/2026	ZVRA Zevra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)

(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANTX Anthem	N/A	N/A	N/A	N/A	$1.94 per share	N/A
AQST Aquestive Therapeutics	$54.09M	11.09	N/A	N/A	($0.28) per share	-17.07
IVA Inventiva	$5.07M	148.33	N/A	N/A	($0.22) per share	-14.36
ZVRA Zevra Therapeutics	$106.47M	6.35	$0.95 per share	12.04	$2.75 per share	4.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANTX Anthem	-$35.17M	-$1.07	N/A	N/A	N/A	N/A	-53.52%	-48.63%	N/A
AQST Aquestive Therapeutics	-$83.78M	-$0.65	N/A	N/A	N/A	-144.63%	N/A	-52.40%	11/4/2026 (Estimated)
IVA Inventiva	-$400.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	$83.23M	$0.92	12.38	13.56	N/A	42.82%	54.54%	34.15%	11/4/2026 (Estimated)

Latest ANTX, ZVRA, IVA, and AQST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	AQST Aquestive Therapeutics	-$0.10	N/A	N/A	N/A	$11.02 million	N/A
11/4/2026	Q3 2026	ZVRA Zevra Therapeutics	$0.14	N/A	N/A	N/A	$37.08 million	N/A
9/28/2026	Q2 2026	IVA Inventiva	-$0.20	-$0.2841	-$0.0841	N/A	$2.88 million	$0.02 million
8/14/2026	Q2 2026 TU	IVA Inventiva	N/A	-$0.1450	N/A	-$0.1450	N/A	$0.75 million
8/11/2026	Q2 2026	ANTX Anthem	N/A	-$0.18	N/A	-$0.18	N/A	N/A
8/11/2026	Q2 2026	AQST Aquestive Therapeutics	-$0.1050	-$0.18	-$0.0750	-$0.18	$11.42 million	$13.82 million
8/5/2026	Q2 2026	ZVRA Zevra Therapeutics	$0.11	$0.25	+$0.14	$0.14	$33.88 million	$39.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANTX Anthem	N/A	N/A	N/A	N/A	N/A
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANTX Anthem	N/A	14.32	14.32
AQST Aquestive Therapeutics	N/A	7.19	6.74
IVA Inventiva	0.90	3.81	N/A
ZVRA Zevra Therapeutics	N/A	5.17	5.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANTX Anthem	90.47%
AQST Aquestive Therapeutics	32.45%
IVA Inventiva	19.06%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
ANTX Anthem	22.61%
AQST Aquestive Therapeutics	6.81%
IVA Inventiva	32.00%
ZVRA Zevra Therapeutics	3.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANTX Anthem	N/A	37.74 million	29.20 million	Not Optionable
AQST Aquestive Therapeutics	147	125.51 million	116.97 million	Optionable
IVA Inventiva	73	237.99 million	161.83 million	Not Optionable
ZVRA Zevra Therapeutics	61	59.38 million	57.19 million	Optionable

ANTX, ZVRA, IVA, and AQST Headlines

Recent News About These Companies

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Rated "Buy" by Wall Street Brokerages

October 8, 2026 | americanbankingnews.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Has Consensus Price Target of $27.14

October 8, 2026 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Stock Jumps 4.6% - Here's Why

October 7, 2026 | marketbeat.com

Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor

October 6, 2026 | seekingalpha.com

Stock Traders Buy High Volume of Put Options on Zevra Therapeutics (NASDAQ:ZVRA)

September 24, 2026 | marketbeat.com

Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Analysts

September 13, 2026 | marketbeat.com

Zevra Therapeutics to Present at Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Zevra Therapeutics Presents Long-Term Real-World Data Supporting MIPLYFFA in Niemann-Pick Disease Type C at SSIEM Annual Symposium

August 25, 2026 | quiverquant.comQ

Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

August 25, 2026 | globenewswire.com

Roth MKM Sticks to Their Buy Rating for Zevra Therapeutics (ZVRA)

August 23, 2026 | theglobeandmail.com

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 21, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 13, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 11, 2026 | globenewswire.com

What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?

August 7, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 6, 2026 | prnewswire.com

Zevra outlines CHMP reexamination timing with Q4 opinion expected, as MIPLYFFA Orange Book listing extends to 2041

August 6, 2026 | seekingalpha.com

Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript

August 5, 2026 | seekingalpha.com

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

August 5, 2026 | zacks.com

Zevra Therapeutics (ZVRA) Releases Q2 2026 Earnings: Revenue Growth and EPS Beat

August 5, 2026 | quiverquant.comQ

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

August 5, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANTX, ZVRA, IVA, and AQST Company Descriptions

Anthem NASDAQ:ANTX

$4.40 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.41 +0.01 (+0.23%)

As of 05:14 AM Eastern

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Aquestive Therapeutics NASDAQ:AQST

$4.78 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.85 +0.07 (+1.46%)

As of 08:20 AM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Inventiva NASDAQ:IVA

$3.16 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.27 +0.11 (+3.39%)

As of 08:27 AM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Zevra Therapeutics NASDAQ:ZVRA

$11.39 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$11.37 -0.02 (-0.20%)

As of 08:27 AM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANTX, ZVRA, IVA, and AQST Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANTX, ZVRA, IVA, and AQST Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANTX, ZVRA, IVA, and AQST Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANTX, ZVRA, IVA, and AQST Company Descriptions

Anthem NASDAQ:ANTX

Aquestive Therapeutics NASDAQ:AQST

Inventiva NASDAQ:IVA

Zevra Therapeutics NASDAQ:ZVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANTX, ZVRA, IVA, and AQST Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANTX, ZVRA, IVA, and AQST Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANTX, ZVRA, IVA, and AQST Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANTX, ZVRA, IVA, and AQST Company Descriptions

Anthem NASDAQ:ANTX

Aquestive Therapeutics NASDAQ:AQST

Inventiva NASDAQ:IVA

Zevra Therapeutics NASDAQ:ZVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools